Sad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes.
Bimagrumab was initially created by MorphoSys, a product of its HuCAL antibody library. It was then licensed to Novartis, which started this phase II/III trial in October 2013 – shortly after receiving FDA Breakthrough Therapy.
The trial enrolled 240 patients with sporadic inclusion body myositis (sIBM), a rare debilitating muscle disease still without an approved treatment.
Recently, Novartis announced that this trial did not meet its primary endpoint – increasing the walking distance of patients in a given timeframe.
The trial is still ongoing, while the data is reviewed to make a decision on the programme –